Revised USPSTF Lung Cancer Screening Guidelines May Benefit Racial Minorities
Research presented at CHEST 2021 examined how expanded USPSTF lung cancer screening criteria would affect minorities and women.
Lung Cancer
An Efficient, Minimally Invasive Pathway to Manage Suspicious Lung Nodules
Research presented at CHEST 2021 examines use of a single anesthesia episode for robotic navigational bronchoscopy and pulmonary resection for lung nodules.
Tecentriq Approved as Adjuvant Treatment for Early NSCLC
The approval was based on data from the phase 3 IMpower010 study.
New USPSTF Guidance Expands Eligibility for Lung Cancer Screening
Newly eligible population includes individuals aged 50 to 54 years, more women, more racial and ethnic-minority groups
Lung Cancer Treatment May Impact Daily Function in Older Adults
Life-space assessments may help older adults better understand how cancer treatment impacts their lives, authors say
Revised Guidelines Perpetuate Disparities in Lung Cancer Screening
In newly revised USPSTF guidelines, African American and Hispanic individuals continue to be less likely to be eligible for lung cancer screening
Durvalumab Plus Chemo Showed Continued Survival Benefit in Extensive-Stage SCLC
Updated results from the phase 3 CASPIAN study further established first-line durvalumab with platinum-etoposide as a standard of care for ES-SCLC.
Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer
Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
MPR Weekly Dose Podcast Episode 93
The FDA weigh up mandatory education for opioid prescribers; There’s an increase in the sale of strong psychoactive THC products; Brukinsa and Exkivity gain approval, respectively; And a number of supplement companies received FDA warning letters.
